September 13, 2021 -- Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.
The companies will develop immune cells with human chimeric antigen receptors and T-cell receptors aimed at disease-specific cell surface antigens, Twist said. Twist will contribute its proprietary single-chain fragment variable and VHH nanobody technologies from its library, which will support Adicet's discovery of new chimeric antigen receptors to generate novel gamma delta CAR T-cell products.
Adicet will pay Twist an upfront licensing fee as well as clinical and regulatory milestone payments and royalties.